Transformative Technologies for Early Cancer Detection.

Identifying viral cancers
earlier than ever before.

Learn More

Improving patient outcomes through early cancer detection.

Naveris develops highly sensitive blood tests, liquid biopsies, that identify viral cancers significantly earlier than is possible with scans or traditional biopsies.

Naveris’ lead product, NavDx®, is a liquid biopsy that uses proprietary technology to enable ultrasensitive surveillance of HPV-related cancer.

NavDx Liquid Biopsy

Our Core Technology

Our mission at Naveris is to deliver disruptive technology with the potential to transform cancer detection and improve patient outcomes.

Highly Sensitive Blood Tests

Early cancer diagnosis in the general asymptomatic population.

Transform Cancer Detection

Real-time monitoring of response in patients undergoing treatment.

Improve Patient Outcomes

Detection of cancer recurrence in patients in remission.

Recent Posts / View All Posts

Natick Company Develops Test to Detect Head and Neck Cancer that Could Lead to Earlier Diagnosis

admin | Publications | No Comments

“A saliva-based diagnostic test that can detect HPV-related head and neck cancer has the potential to catch the disease earlier and even serve as a standard screening method, which the…

New Saliva Test Detects Head and Neck Cancer

admin | Press Release | No Comments

For Release: June 2, 2021 Waltham, MA— A new clinically-validated saliva test has been shown to detect HPV-associated head and neck cancer with high accuracy, a first-of-its-kind study result. Researchers…

Naveris, Inc. Raises $19 Million in Financing to Advance and Commercialize Blood Tests for Early Detection of HPV and Other Viral-Related Cancers